Clinical Trials Logo

Clinical Trial Summary

Dementia with Lewy bodies (DLB) is the second most common cause of dementia and is associated with parkinsonism, hallucinations, and cognitive fluctuations. Diagnosis is often either missed or delayed due to physician lack of familiarity with characteristic features, the inability of structural MRI to detect a pathological signature for this condition, and the lack of healthcare provider access to "indicative biomarkers" that are either unavailable at community clinics or costly due to lack of insurance coverage. The role of resting state function MRI (rs-fMRI) as a diagnostic biomarker has been underexplored in this disease. We propose using a novel cloud-based automated imaging software processing program that identifies abnormal brain networks or connectomes using resting state functional MRI (rs-fMRI) and data from the Human Connectome Project (HCP). Furthermore, the imaging protocol to capture this data is relatively short (15 minutes) and can be performed at most imaging centers, lending potential clinical applicability to this study. We intend to study dysfunctional large scale brain networks (LSBNs) in DLB by comparing rs-fMRI imaging data in this population with cognitively normal (CN) and mild Alzheimer's disease (AD) subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI)-2/3 database.


Clinical Trial Description

Omniscient, a for-profit, Sydney, Australia-based company, created the cloud-based software Infinitome, a program that utilizes data from the Human Connectome Project (HCP) together with machine learning to analyze diffusion tensor and resting-state fMRI imaging data from remote sites. The foundation for this imaging tool is based upon the HCP atlas, which has also informed prior publications from our group, including the Connectomic Atlas of the Human Cerebrum (Baker, Burks, Briggs, Conner, et al. 2018). The Infinitome program creates a subject specific version of the Human Connectome Project Multimodal Parcellation (HCP-MMP1) atlas using diffusion tractography. Analytics are performed on both diffusion tensor imaging and rs-fMRI. Outlier detection using a tangent space connectivity matrix is performed by comparing results with a subset of 300 normal HCP subject fMRI samples to determine the range of normal correlations for each regions of interest in a large scale brain network which include: 1. Locus coeruleus vs. Nucleus basalis of Meynert 2. Locus coeruelus vs. Intralaminar nucleus of the thalamus 3. Nucleus basalis of Meynert vs. Intralaminar nuclei of the thalamus 4. FST in the vs. Area PH in the lateral occipital lobe 5. Substantia nigra vs. Caudate nucleus Clinical Measures will be correlated with functional connectivity scores to identify relationship between clinical symptoms and large scale brain networks in DLB ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04773041
Study type Observational
Source HealthPartners Institute
Contact
Status Completed
Phase
Start date April 27, 2021
Completion date June 19, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03996460 - K0706 for Patients Diagnosed With Dementia With Lewy Bodies Phase 2
Recruiting NCT04335994 - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing N/A
Recruiting NCT02194816 - Modifiable Variables in Parkinsonism (MVP)
Active, not recruiting NCT01208675 - The Swedish BioFINDER Study
Completed NCT03538522 - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 Phase 2
Recruiting NCT03672448 - The China Longitudinal Aging Study of Cognitive Impairment
Completed NCT01340001 - Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies N/A
Not yet recruiting NCT04760860 - Terazosin for Dementia With Lewy Bodies Phase 1/Phase 2
Terminated NCT02928445 - Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension Phase 2/Phase 3
Completed NCT02910102 - Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia Phase 2
Terminated NCT02871427 - Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder Phase 2
Completed NCT05188105 - Alpha tACS in Dementia With Lewy Bodies N/A
Active, not recruiting NCT04167813 - Trial of Ondansetron as a Parkinson's HAllucinations Treatment Phase 2
Enrolling by invitation NCT04954183 - Development of an EEG Diagnostic for Alzheimer's Disease
Recruiting NCT05326750 - Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases N/A
Completed NCT01023672 - "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies" Phase 4
Completed NCT03907748 - Home-based Family Caregiver-delivered Music and Reading Interventions for People With Dementia N/A
Completed NCT04649164 - Learning to PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia N/A
Recruiting NCT03924414 - Trial of Parkinson's And Zoledronic Acid Phase 4
Completed NCT05885620 - SAMi Intervention Study to Evaluate Smartwatch Interventions in Persons With MCI and Dementia N/A